Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-856.00K | 0.00 | -3.27M | -3.31M | -3.41M | -667.00K | EBIT |
-182.91M | -154.07M | -143.72M | -145.60M | -130.71M | -63.47M | EBITDA |
-181.29M | -134.75M | -141.57M | -143.49M | -128.57M | -62.80M | Net Income Common Stockholders |
-167.38M | -138.20M | -134.24M | -138.29M | -127.79M | -62.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
263.70M | 312.02M | 259.72M | 242.66M | 242.72M | 351.21M | Total Assets |
303.03M | 350.07M | 297.67M | 285.10M | 287.04M | 355.95M | Total Debt |
28.31M | 28.97M | 31.36M | 32.86M | 34.59M | 0.00 | Net Debt |
-68.81M | -20.53M | -193.75M | -107.16M | -40.25M | -268.56M | Total Liabilities |
59.24M | 56.97M | 47.12M | 53.90M | 55.13M | 11.67M | Stockholders Equity |
243.79M | 293.11M | 250.56M | 231.19M | 231.91M | 344.28M |
Cash Flow | Free Cash Flow | ||||
-139.88M | -118.02M | -121.33M | -122.83M | -107.76M | -53.55M | Operating Cash Flow |
-139.79M | -118.01M | -121.14M | -116.31M | -106.11M | -53.09M | Investing Cash Flow |
-43.88M | -218.80M | 70.70M | 58.44M | -88.24M | -83.16M | Financing Cash Flow |
128.85M | 161.21M | 135.52M | 122.91M | 1.79M | 360.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $372.46M | ― | -0.23% | ― | 3087.25% | 97.11% | |
55 Neutral | $243.52M | ― | 2152.93% | ― | ― | 54.68% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
46 Neutral | $513.79M | ― | -61.35% | ― | 10.10% | -7.25% | |
43 Neutral | $126.46M | ― | -262.12% | ― | 239.92% | 79.41% | |
41 Neutral | $189.59M | ― | -160.99% | ― | -75.67% | -552.37% | |
38 Underperform | $289.65M | ― | -66.13% | ― | ― | 43.21% |
Annexon Biosciences has appointed William Jones to its Board of Directors, bringing his extensive 30-year experience in the biotechnology industry to the company. This strategic move comes as Annexon prepares for the commercialization of key treatments for Guillain-Barré Syndrome and geographic atrophy, with Jones’ commercial expertise expected to enhance the company’s market positioning and execution of its commercialization strategies.